Members, Observers, and Jurisdictions That Are Neither

Part of Regulatory Affairs and the Jurisdiction Map: The Global GCP Baseline.

About 6 minutes. Free, in your language, no account needed.

Why this matters

People use "ICH country" as though it were a binary. It is not, and the distinction carries real consequences for what you can assume and what you must verify.

The International Council for Harmonisation has several categories of participation. A regulatory authority can be a Regulatory Member, with a formal role in developing and implementing the guidelines. An organization can be an Observer, engaged but without that role. And a great many countries are neither, while still applying E6 as their national standard because it is the best available and rewriting it would serve nobody.

All three groups can be running your trial. Only one of them has committed, as a member, to implement what the Council agrees.

What each status means in practice

Regulatory Member. The authority participates in developing the guidelines and commits to implementing them. If an authority is a Regulatory Member, you can reasonably expect E6(R3) to be reflected in its national framework, and you can expect the authority to know the guideline in detail.

Observer. The organization is engaged with the Council's work without the membership commitment. Observer status tells you there is genuine engagement. It does not tell you that any particular guideline has been implemented nationally, and that remains a question to verify rather than assume.

Neither. A country that is neither a member nor an observer may still apply E6 as national guidance, and many do. Here the governing text is the national instrument that adopts it, and what binds you is that instrument rather than the guideline.

The distinction between the second and third groups matters less than people think. What matters in both is the same: name the national instrument. Status tells you how likely you are to find alignment. It never tells you what the law says.

Worked examples from the verified register

CRLN's register records the status with the national instrument, because one without the other misleads.

Argentina is recorded as an ICH Regulatory Member, and its national instrument is Disposición ANMAT 6677/2010, the Régimen de Buena Práctica Clínica en Estudios de Farmacología Clínica. The authority is ANMAT. Argentina does not appear on the WHO maturity level 3 or 4 list as of the register's reference date.

Nigeria is also recorded as an ICH Regulatory Member, with the NAFDAC Act, Cap F33 LFN 2004, the Good Clinical Practice Regulations 2009, and the NAFDAC Good Clinical Practice Guidelines 2020. NAFDAC is benchmarked at maturity level 3 for medicines and vaccines as a non-producing country.

South Africa, likewise a Regulatory Member, works under the Medicines and Related Substances Act 101 of 1965, Regulation 30, with the South African Good Clinical Practice guidelines, third edition 2020, whose compliance is compulsory. SAHPRA is benchmarked at maturity level 3 for vaccines as a producing country.

India is recorded as an Observer. Its national instrument is the New Drugs and Clinical Trials Rules, 2019, First Schedule, which superseded the older Schedule Y. CDSCO is benchmarked at maturity level 3 for vaccines as a producing country.

Kenya and Pakistan are neither members nor observers, and both apply E6(R3) as national guidance. Kenya works under the Pharmacy and Poisons Act, Cap 244 with the 2022 guidelines for the conduct of clinical trials; Pakistan under the DRAP Act 2012 and the Bio-Study Rules 2017, with oversight by the Clinical Studies Committee.

Read those five together and the lesson is plain. Two Regulatory Members have different maturity scopes. An Observer and a non-participant both have precise, citable national instruments. Status predicts nothing you can rely on without the instrument beside it.

The trap: inferring from the region

The most common error is regional inference. A team verifies one country in a region, finds a framework, and assumes the neighbors match.

They frequently do not. Regulatory frameworks follow legal traditions, colonial legal inheritance, membership of economic communities, and the individual history of each authority. Two neighboring countries can have entirely different instruments, entirely different clocks, and entirely different requirements for a local sponsor representative.

CRLN's register holds 200 jurisdictions, of which 45 are verified against a named primary instrument. The other 155 record the global baseline as an inference. That is not a deficiency to hide. It is an honest statement of what has been checked, and it is exactly the statement that allows someone to rely on the 45.

In practice

A sponsor is planning a trial across six African countries and asks the regulatory lead for the submission requirements.

The lead has verified instruments for three: Nigeria, South Africa and Kenya. For the other three, the register holds an inference from the baseline and no verified national instrument.

The weak answer describes all six as "ICH GCP jurisdictions, standard requirements." It is comfortable, it is what the study team wants to hear, and it converts an unverified inference into a statement of fact.

The strong answer gives three countries with named instruments, named authorities and known expectations, and three countries flagged as requiring verification before a timeline can be committed, with an estimate of how long verification takes. The study team can plan around the second answer. They cannot plan around the first, because they do not know it is soft.

What this looks like when it goes wrong

A trial opens in a country where the sponsor assumed the regional pattern held. It did not: that country requires a locally established sponsor representative with legal responsibility inside the country, and the sponsor has none.

The discovery comes not at submission but three months in, when the authority writes asking who its legal correspondent is. The trial has already enrolled participants. There is now no clean answer, because establishing the representative takes weeks and the participants are already in the trial.

The requirement was findable. Nobody looked, because the neighboring country did not have it.

Key takeaways